← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #353 OF 1,000 MOST-CITED

Design input - Lack of or inadequate procedures

FDA cited this observation 59 times across 58 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices59
BY FISCAL YEAR
FY20261
FY20256
FY20244
FY20237
FY20225
FY20214
FY20205
FY201911
FY20188
FY20178

How FDA worded it — real examples

Procedures for design input have not been adequately established.

Ashland Specialty Ingredients, G.P. · Fiskeville, Rhode Island · Devices · 2025-12-22

Procedures for design input have not been adequately established.

Medical Instrument Development Laboratories, Inc. · San Leandro, California · Devices · 2025-08-13

Procedures for design input have not been adequately established.

Fresenius Kabi USA, LLC · North Andover, Massachusetts · Devices · 2025-08-08

Procedures for design input have not been adequately established.

Miach Orthopaedics · Westborough, Massachusetts · Devices · 2025-04-23

Procedures for design input have not been adequately established.

Vonco Products, LLC · Trevor, Wisconsin · Devices · 2025-04-10

Procedures for design input have not been adequately established.

NeuroSync, Inc. · Holliston, Massachusetts · Devices · 2025-02-05

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemMedical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →